Lack of association of human immunodeficiency virus seroconversion with visits to foreign ports in US Navy personnel.

BACKGROUND: The US Navy visits ports on all continents and many islands of the world, many of which are reported to have a high endemicity of human immunodeficiency virus (HIV) infection. The objective of this study was to determine whether visits to foreign ports by active-duty navy personnel were associated with increased risk of HIV infection. METHODS: The Naval Health Research Center in San Diego, Calif, maintains records of all HIV enzyme-linked immunosorbent assay and Western blot tests given in the navy. This information, along with career histories and ship movement data, was used in a nested case-control design to examine the relationship between visits to the 100 foreign ports most frequently visited by the navy and risk of HIV seroconversion. All visits to a port and total time in each port during the study period were examined. A total of 813 seroconverters were matched to 6993 seronegative active-duty controls by age, race, sex, occupational group, home port, and year of test. RESULTS: Estimated relative risks of seroconversion associated with visits to foreign ports showed no statistically significant excess risk of HIV infection for navy personnel after visits to any foreign port. CONCLUSIONS: These results do not imply that an individual's risk of acquisition of HIV would be less in a foreign port if the individual engaged in high-risk activity there. Rather, they imply that despite the mobility of the US Navy and the large variation in HIV seroprevalence rates throughout the world, navy personnel generally do not appear to be acquiring HIV infections abroad.

Decline in human immunodeficiency virus seropositivity and seroconversion in US Navy enlisted personnel: 1986 to 1989. Navy HIV Working Group.

The US Navy administered 1,795,578 enzyme-linked immunosorbent assay (ELISA) tests to 848,632 active-duty Navy enlisted personnel during 1986 to 1989. This study identified 2438 human immunodeficiency virus (HIV)-seropositive active-duty enlisted Navy personnel, including 778 seroconverters. Three types of quarterly rates of HIV seropositivity and seroconversion were determined. All three rates declined. This decline could not be explained by changes in the population tested according to age, race, sex, occupation, or geographic location of home port.

In vivo inhibitors of Escherichia coli phenylalanyl-tRNA synthetase.

N-Benzyl-D-amphetamine is a potent in vitro and in vivo inhibitor of phenylalanyl-tRNA synthetase of Escherichia coli. The concentration of this inhibitor necessary for the in vivo inhibition is approximately 100-fold greater than that necessary for inhibition of the purified enzyme. Treatment of rel+ strains of E. coli with the inhibitor results in a decreased percentage of tRNA Phe which is charged, guanosine tetraphosphate formation, cessation of RNA synthesis, and growth arrest. Evidence is presented which demonstrates that the primary and perhaps sole mode of action of N-benzyl-D-amphetamine is inhibition of phenylalanyl-tRNA synthetase.